As such, GLP-1 not only represents a target for therapeutic interventions in the management of diabetes and obesity but also serves as a focal point for preventive strategies aimed at maintaining metabolic health and preventing the onset of metabolic disorders
35 Clinical data are limited regarding the use of DPP-4 inhibitors to prevent retinopathy
If its been more than 48 hours, contact our team and we can determine the right course of action, whether thats waiting for your next dose or taking less than usual
The lineup includes the Wegovy pill (oral semaglutide, FDA-approved December 2025, launched January 2026, the first FDA-approved oral GLP-1 for weight loss in adults), the Wegovy pen (injectable semaglutide 2.4 mg), Zepbound (tirzepatide via LillyDirect), and Ozempic (off-label for weight loss)
Ro and Hers help you use it
This technique helps ensure the medication is injected into the subcutaneous layer rather than deeper muscle tissue, which can affect absorption and cause pain